CLNN — Clene Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1822791 ·
Last close
$6.57
Market Cap
$83.95M
52W High
$8.67
52W Low
$4.45
ADV30
929,109
Next earnings
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 15,000 15,000 -1,692,000 -8,091,000 21,665,000 5,939,000 40,471,000
Dec 2025 77,000 54,000 -7,244,000 -9,226,000 18,131,000 5,189,000 35,723,000
Sep 2025 15,000 15,000 -5,373,000 -8,777,000 22,311,000 7,925,000 34,668,000
Jun 2025 27,000 27,000 -5,628,000 -7,419,000 22,125,000 7,285,000 30,675,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,546,000
Investing CF
$-39,000
Financing CF
$11,518,000
CapEx
$-30,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.94
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-308,296,000
Inventory
$37,000
Receivables
$590,000
ST Investments
$0
EBIT TTM
$-23,491,000
Pretax Income TTM
$-26,173,000
Interest Exp TTM
$2,682,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$134,000
EBITDA
$-19,622,000
Free Cash Flow
$-11,576,125
Enterprise Value
$101,723,656
Total Cash
$5,939,000
Total Debt
$22,048,000
Shares Out
12,778,307
Trailing EPS
$-3.27
Book Value
$-1.60
ROE
ROA
-56.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 200,000 -21,816,000 -26,173,000 18,131,000 35,723,000 -18,546,000
Dec 2024 342,000 -31,975,000 -39,400,000 27,337,000 36,194,000 -21,326,000
Dec 2023 654,000 -38,260,000 -49,504,000 52,341,000 38,951,000 -30,171,000
Dec 2022 473,000 -44,557,000 -29,918,000 44,493,000 41,256,000 -39,011,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.43

Peers — same industry

TickerNameMarket CapLastDaily %
CPIX CUMBERLAND PHARMACEUTICALS INC $86.45M $5.77
CUE Cue Biopharma, Inc. $81.04M $20.03
MAIA MAIA Biotechnology, Inc. $80.87M $1.33
LFVN Lifevantage Corp $87.43M $6.93
ANVS Annovis Bio, Inc. $87.64M $2.06

News headlines (Yahoo Finance, 1h cache)

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
2026-05-22 00:58 · Yahoo
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?
2026-05-19 13:40 · Yahoo
3 Growth Stocks Insiders Are Betting On
2026-05-18 17:35 · Yahoo
Hennessy Capital Investment VII And 2 Insider-Favored Growth Stocks To Watch
2026-05-18 11:35 · Yahoo
Top Growth Companies With High Insider Ownership May 2026
2026-05-15 17:35 · Yahoo
3 High-Growth Insider-Owned Companies With Earnings Surging Up To 80%
2026-05-15 11:35 · Yahoo
3 Growth Companies With High Insider Ownership And Up To 71% Earnings Growth
2026-05-14 17:36 · Yahoo
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
2026-05-14 13:10 · Yahoo
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
2026-05-14 12:00 · Yahoo
3 Growth Companies With High Insider Ownership And 27% Revenue Growth
2026-05-14 11:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.